文献速递妇科产科

接受激素治疗的乳腺癌女性妇科服务利用情况

Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
PubMed 文献 · Am J Obstet Gynecol · 2017-03-21

基于MarketScan数据库2009至2013年75,170例乳腺癌术后女性,比较他莫昔芬(<50岁与≥50岁)与≥50岁芳香化酶抑制剂使用者的妇科症状、病理及操作发生率,发现他莫昔芬组均更高,作者呼吁减少无症状女性的妇科干预。

要点

  • 他莫昔芬<50岁组、他莫昔芬≥50岁组与芳香化酶抑制剂≥50岁组任何妇科症状或病理诊断累积发生率分别为20.2%、12.3%、3.5%(P<.001)。
  • 三组任何妇科操作或干预累积发生率分别为34.2%、20.9%、9.0%(P<.0001)。
  • 无症状或无病理女性中,三组干预实施率分别为20.0%、11.0%、6.8%(P<.0001)。

核心结论

  • 与使用芳香化酶抑制剂的女性相比,使用他莫昔芬的绝经前和绝经后乳腺癌女性妇科症状、操作及病理发生率均更高。
  • 需要加强努力以减少无症状女性的妇科干预使用。

研究设计与样本

  • 基于MarketScan数据库的人群分析,纳入2009年至2013年诊断为乳腺癌并接受乳房切除术或肿块切除术的女性。
  • 共75,170例女性,包括15,735例(20.9%)<50岁使用他莫昔芬者、13,827例(18.4%)≥50岁使用他莫昔芬者、45,608例(60.7%)≥50岁使用芳香化酶抑制剂者。
  • 比较他莫昔芬组(<50岁 vs ≥50岁)与≥50岁芳香化酶抑制剂组的妇科症状、疾病及操作干预,并进行时间依赖性分析。

主要发现

  • 研究期间任何妇科症状或病理诊断的累积发生率:他莫昔芬<50岁组20.2%、他莫昔芬≥50岁组12.3%、芳香化酶抑制剂≥50岁组3.5%(P<.001)。
  • 研究期间任何妇科操作或干预的累积发生率:他莫昔芬<50岁组34.2%、他莫昔芬≥50岁组20.9%、芳香化酶抑制剂≥50岁组9.0%(P<.0001)。
  • 无症状或无病理女性中实施干预的比例:他莫昔芬<50岁组20.0%、他莫昔芬≥50岁组11.0%、芳香化酶抑制剂≥50岁组6.8%(P<.0001)。

临床怎么用

  • 作者认为,与芳香化酶抑制剂相比,他莫昔芬使用者的妇科症状、操作及病理发生率更高。
  • 作者建议,需要加强努力以减少无症状女性的妇科干预使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The selective estrogen receptor modulator tamoxifen is now widely used for the treatment and prevention of breast cancer. Tamoxifen use has been associated with a variety of gynecologic problems. Despite the frequency with which hormonal therapy is used for the treatment of breast cancer, limited population-level data are available to describe the occurrence of gynecologic conditions and the use of surveillance testing in women receiving tamoxifen and aromatase inhibitors. OBJECTIVE: We performed a population-based analysis among women with breast cancer receiving hormonal therapy with tamoxifen, a drug commonly used in premenopausal and sometimes postmenopausal women, to determine the frequency of gynecologic abnormalities and use of diagnostic and surveillance testing. We compared these findings to women treated with aromatase inhibitors, agents commonly used in postmenopausal women. STUDY DESIGN: The MarketScan database was used to identify women diagnosed with breast cancer from 2009 through 2013 who underwent mastectomy or lumpectomy. Women receiving tamoxifen (age <50 vs ≥50 years) were compared to women ≥50 years of age treated with aromatase inhibitors. We examined the occurrence of gynecologic symptoms and diseases (vaginal bleeding, endometrial polyps, endometrial hyperplasia, and endometrial cancer) and gynecologic procedures and interventions (transvaginal ultrasound, endometrial biopsy, hysteroscopy/dilation and curettage, and hysterectomy). Time-dependent analyses were performed to examine symptoms and testing. RESULTS: A total of 75,170 women, including 15,735 (20.9%) age <50 years treated with tamoxifen, 13,827 (18.4%) age ≥50 years treated with tamoxifen, and 45,608 (60.7%) age ≥50 years treated with aromatase inhibitors were identified. The cumulative incidence of any gynecologic symptom or pathologic diagnosis during the study period was 20.2%, 12.3%, and 3.5%, respectively (P < .001), while the cumulative incidence of any gynecologic procedure or intervention during the study period was 34.2%, 20.9%, and 9.0%, respectively (P < .0001). Among women without symptoms or pathology, interventions were performed in 20.0%, 11.0%, and 6.8%, respectively (P < .0001). CONCLUSION: Compared to women taking aromatase inhibitors, gynecologic symptoms, procedures, and pathology are higher for both premenopausal and postmenopausal women with breast cancer on tamoxifen. Increased efforts to curb use of gynecologic interventions in asymptomatic women are needed.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wright JD, Desai VB, Chen L, et al. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. Am J Obstet Gynecol. 2017. PMID: 28341383. doi:10.1016/j.ajog.2017.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。